17:36 , Sep 7, 2018 |  BC Week In Review  |  Company News

MannKind stock climbs after closing treprostinil deal with United Therapeutics

MannKind Corp. (NASDAQ:MNKD; Tel Aviv:MNKD) shot up $0.98 (89%) to $2.08. on Sept. 4 after signing a deal with United Therapeutics Corp. (NASDAQ:UTHR) for rights to Treprostinil Technosphere. MannKind will receive $45 million up front...
08:00 , Jan 11, 2016 |  BC Week In Review  |  Company News

MannKind, Sanofi deal

Sanofi terminated an August 2014 deal with MannKind granting the pharma exclusive, worldwide rights to develop and commercialize Afrezza to treat adults with Type I or II diabetes. Sanofi said the decision, effective July 4...
02:08 , Jan 6, 2016 |  BC Extra  |  Company News

Sanofi ends Afrezza deal with MannKind

MannKind Corp. (NASDAQ:MNKD) sank $0.70 (48%) to $0.75 on Tuesday after Sanofi (Euronext:SAN; NYSE:SNY) terminated the companies' deal for Afrezza inhaled insulin. Sanofi spokesperson Susan Brooks said the decision was based in part on "the...
07:00 , May 18, 2015 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes...
08:00 , Feb 23, 2015 |  BC Week In Review  |  Company News

MannKind Corp, Sanofi sales and marketing update

Sanofi launched Afrezza in the U.S. to treat adults with Type I and II diabetes. The wholesale acquisition cost (WAC) is $226.06 for two inhalers. Sanofi has exclusive, worldwide rights to develop and commercialize Afrezza...
01:42 , Feb 21, 2015 |  BC Extra  |  Top Story

Sanofi's pick checks boxes in emerging markets, established products

Investors had a muted response to the appointment of Olivier Brandicourt as the new CEO at Sanofi (Euronext:SAN; NYSE:SNY), as the pharma's shares shed EUR 0.45 to EUR 87.39 on Euronext and were unchanged at...
08:00 , Jan 12, 2015 |  BioCentury  |  Finance

Buyside view XXIII: Milestones galore

Stephen Hansen, Associate Editor and Jennifer Rhodes, Staff Writer   Buyside view XXIII The maturation of the biotech sector over the past few years finds fund managers focusing on a slew of clinical milestones and...
08:00 , Nov 17, 2014 |  BioCentury  |  Strategy

Lantus limbo

The abrupt slowing of Lantus sales in the U.S. could augur reimbursement pressure for new insulin candidates entering the market from Sanofi and its competitors. A halving of U.S. sales growth for Lantus insulin glargine...
08:00 , Nov 17, 2014 |  BioCentury  |  Strategy

Poste a pourvoir

Job one for Sanofi 's next CEO will be to shore up revenues, a task that may be difficult since the board has taken major acquisitions off the table and all the products in the...
04:41 , Oct 29, 2014 |  BC Extra  |  Financial News

Diabetes, not CEO, dominates Sanofi earnings

American depository shares of Sanofi (Euronext:SAN; NYSE:SNY) fell $4.75 to $48.07 in New York on Tuesday as the company revealed that sales in its diabetes franchise would be flat in 2015 primarily because of competitive...